Jim Hoffman: Could Extracorporeal Removal of NETs Become a ‘Holy Grail’ Therapy Across Multiple Diseases?
Jim Hoffman, Former Technical Advisor at Cygnus Technologies, LLC, shared a post on LinkedIn about a recent article by Michal Santocki and Elzbieta Kolaczkowska, published in Cells:
“Could extracorporeal removal of NETs and other extracellular chromatin outperform many drug treatments with the potential to be a holy grail treatment for multiple diseases and disorders, slowing their progression and aiding recovery, largely free of systemically administered drug-related side effects?
Recent evidence, courtesy of Santersus AG, treating severe Lupus, and backed by over two decades of NETosis research, suggests we should pay much more attention to the universal potential of this therapy to transform disease management, since dysregulated NETosis contributes to the progression of most, if not all, diseases.”
Title: On Neutrophil Extracellular Trap (NET) Removal: What We Know Thus Far and Why So Little
Authors: Michal Santocki, Elzbieta Kolaczkowska
Read the Full Article on Cells.
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 5, 2026, 03:30Rob Maloney: Who Are the Real Experts? – The Quiet Resilience of the Bleeding Disorders Community
-
Sep 5, 2026, 03:26Project Elevate Her – Scaling Heights for Bleeding Disorders Awareness – WFH
-
Sep 5, 2026, 03:20Sarah Bassiony: How Do non-Specialists Learn Haematology? – Participate in Our Remote Study
-
Sep 5, 2026, 03:13Omid Seidizadeh: Uncovering the Genetic Architecture of Low Von Willebrand Factor
-
Sep 5, 2026, 03:07Luke McLaughlin: The First Community Article of the Haemophilia Rights Project
-
Sep 5, 2026, 03:00Panagiotis Christoforou: Proud to Contribute to Barts Health’s Leading Role in UK Clinical Trials
-
Sep 5, 2026, 02:51Kassiani Maria Nastouli: Honored to Be Cited in the New ESC Guidelines on the Management of CVD and CKD
-
Sep 5, 2026, 02:44Sedat Gül: Is It Time to Reconsider the 24-Hour Antiplatelet Delay After Thrombolysis?
-
Sep 5, 2026, 02:35Balaji Balagani: Exploring Stable vs Unstable vs Complete Coronary Block